AstraZeneca (AZN)
(Delayed Data from NSDQ)
$77.35 USD
+0.48 (0.62%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $77.36 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$77.35 USD
+0.48 (0.62%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $77.36 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
Zacks News
Can Merck (MRK) Keep the Beat Streak Alive in Q4 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports fourth-quarter earnings.
Pfizer (PFE) to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
Pfizer's (PFE) revenues are expected to have declined in the fourth quarter of 2023 due to a steep decline in sales of its COVID-19 products on lower demand.
AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
AstraZeneca's (AZN) Imfinzi Combo Meets Liver Cancer Study Goal
by Zacks Equity Research
Data from a late-stage shows that AstraZeneca's (AZN) cancer combination therapy reduces the risk of disease progression or death in certain liver cancer patients by 23%.
Will the Individual MA Unit Aid Humana's (HUM) Q4 Earnings?
by Zacks Equity Research
Humana's (HUM) Q4 results are likely to gain from growing premiums and an expanding customer base within its individual Medicare Advantage and Medicaid units, partly offset by higher marketing spend.
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Zacks Analyst Blog Highlights Microsoft, Procter & Gamble, AstraZeneca, General Electric and Boston Scientific
by Zacks Equity Research
Microsoft, Procter & Gamble, AstraZeneca, General Electric and Boston Scientific are included in this Analyst Blog.
Here's Why Astrazeneca (AZN) Gained But Lagged the Market Today
by Zacks Equity Research
In the closing of the recent trading day, Astrazeneca (AZN) stood at $66.54, denoting a +0.03% change from the preceding trading day.
Top Research Reports for Microsoft, Procter & Gamble & AstraZeneca
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), The Procter & Gamble Company (PG) and AstraZeneca PLC (AZN).
Astrazeneca (AZN) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
J&J (JNJ) Gears Up to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.
Astrazeneca (AZN) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $66.52, moving +0.41% from the previous trading session.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is it a Good Idea to Buy Fusion Pharmaceuticals (FUSN) Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in Fusion Pharmaceuticals (FUSN) stock now may turn out to be a prudent move.
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and AstraZeneca
by Zacks Equity Research
Eli Lilly, Novo Nordisk, Amgen and AstraZeneca are included in this Analyst Blog.
Astrazeneca (AZN) Laps the Stock Market: Here's Why
by Zacks Equity Research
In the latest trading session, Astrazeneca (AZN) closed at $69.42, marking a +0.35% move from the previous day.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
FDA Finds No Link Between Obesity Drugs and Suicidal Thoughts
by Kinjel Shah
The GLP-1 segment is an important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity.
Here's Why Astrazeneca (AZN) Fell More Than Broader Market
by Zacks Equity Research
Astrazeneca (AZN) closed at $69.18 in the latest trading session, marking a -0.56% move from the prior day.
AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Astrazeneca (AZN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
The latest trading day saw Astrazeneca (AZN) settling at $68.38, representing a -0.58% change from its previous close.
Novo Nordisk (NVO) Up on $1.1B Research Deals With 2 Biotechs
by Zacks Equity Research
Novo Nordisk (NVO) gains 4% after signing $1.1 billion research collaboration agreements with two biotech companies to develop novel treatment approaches for cardiometabolic diseases.
Pharma Stock Roundup: LLY's New Digital Pharmacy, NVO & ABBV's Fresh R&D Deals
by Kinjel Shah
Eli Lilly (LLY) launches a new direct-to-consumer website to provide easy access to its medicines. Novo Nordisk (NVO) announces two research collaborations to develop novel treatments for cardiometabolic diseases.
Why the Market Dipped But Astrazeneca (AZN) Gained Today
by Zacks Equity Research
Astrazeneca (AZN) reachead $68.78 at the closing of the latest trading day, reflecting a +0.67% change compared to its last close.
Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $67.35, moving +0.07% from the previous trading session.